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Secreted frizzled related protein 2 (SFRP2) is a tumor endothelial marker expressed in
angiosarcoma. Previously, we showed ultrasound molecular imaging with SFRP2-tar-
geted contrast increased average video pixel intensity (VI) of angiosarcoma vessels by
2.2 ± 0.6 VI versus streptavidin contrast. We hypothesized that redesigning our contrast
agents would increase imaging performance. Improved molecular imaging reagents were
created by combining NeutrAvidin™-functionalized microbubbles with biotinylated SFRP2
or IgY control antibodies. When angiosarcoma tumors in nude mice reached 8 mm, time-
intensity, antibody loading, and microbubble dose experiments optimized molecular
imaging. 10 minutes after injection, the control-subtracted time-intensity curve (TIC) for
SFRP2-targeted contrast reached a maximum, after subtracting the contribution of free-
flowing contrast. SFRP2 antibody-targeted VI was greater when contrast was formulated
with 10-fold molar excess of maleimide-activated NeutrAvidin™ versus 3-fold (4.5 ± 0.18
vs. 0.32 ± 0.15, VI ± SEM, 5 x 106 dose, p < 0.001). Tumor vasculature returned greater
average video pixel intensity using 5 x 107 versus 5 x 106 microbubbles (21.2 ± 2.5 vs. 4.5
± 0.18, p = 0.0011). Specificity for tumor vasculature was confirmed by low VI for SFRP2-
targeted, and control contrast in peri-tumoral vasculature (3.2 ± 0.52 vs. 1.6 ± 0.71, p =
0.92). After optimization, average video pixel intensity of tumor vasculature was 14.2 ± 3.0
VI units higher with SFRP2-targeted contrast versus IgY-targeted control (22.1 ± 2.5 vs.
7.9 ± 1.6, p < 0.001). After log decompression, 14.2 ΔVI was equal to ~70% higher signal,
in arbitray acoustic units (AU), for SFRP2 versus IgY. This provided ~18- fold higher
acoustic signal enhancement than provided previously by 2.2 ΔVI. Basing our targeted
contrast on NeutrAvidin™-functionalized microbubbles, using IgY antibodies for our con-
trol contrast, and optimizing our imaging protocol significantly increased the SFRP2-
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specific signal returned from angiosarcoma vasculature, and may provide new opportuni-
ties for targeted molecular imaging.
Introduction
Angiogenesis is the formation of new capillaries from existing microvasculature. There is a
critical need for non-invasive imaging techniques that examine molecular events associated
with the angiogenic process that could prove invaluable for improving specificity for diagnos-
ing malignancies. One strategy for studying angiogenesis is ultrasound molecular imaging,
which differs from traditional ultrasound imaging in that targeted contrast agents selectively
adhere to endothelial biomarkers of interest, such as markers over-expressed in tumor angio-
genesis [1,2].
Biomarkers specific to tumors could increase the sensitivity and specificity of traditional
imaging techniques. In ultrasound molecular imaging, targeted microbubble contrast binds to
endothelial markers directed by a targeting moiety such as an antibody or receptor ligand.
Bound microbubbles, under ultrasound energy, then display detectable acoustic backscatter.
Several potential applications of ultrasound molecular imaging exist. Molecular imaging of
tumor endothelial markers may help better discriminate between benign and malignant dis-
ease [3,4]. After tumor treatment, molecular imaging may provide early indication of tumor
response, as molecular changes may precede changes in tumor volume [2,5].
Ultrasound has several advantages over other imaging modalities such as MRI and CT.
MRI is expensive, slow, and not widely available in rural locations. The cost of portable ultra-
sound systems is very affordable—typically only 1/100th of a MRI system [6], and unlike CT
scans, ultrasound does not require ionizing radiation, and clinically approved ultrasound con-
trast agents are well tolerated [7].
The development of strategies for monitoring the angiogenic process depends upon identify-
ing targets with biosignatures unique to tumor angiogenesis. To discover proteins overexpressed
in tumor vessels, we developed a novel method for immuno-laser capture microdissection cou-
pled with RNA amplification and genome-wide gene expression to profile tumor vasculature
cells from human breast tumors with comparison to normal breast samples [8]. In our analysis,
we identified that secreted frizzle related protein 2 (SFRP2) mRNA was increased more than
6-fold in breast cancer endothelium. We validated localization and overexpression of SFRP2 in
tumor endothelium at the protein level as shown by immunohistochemistry in breast, colon,
pancreas, renal, prostate, hepatocellular carcinoma, and angiosarcoma [8]. We further discov-
ered that SFRP2 is a novel stimulator of angiogenesis in vivo [9] and in vitro, and that antago-
nism of SFRP2 with a mouse monoclonal antibody inhibited triple negative breast carcinoma
and angiosarcoma growth in mice [10].
We previously created an antibody-labeled contrast by conjugating biotinylated polyclonal
SFRP2 antibodies to biotin-activated microbubble ultrasound contrast using a streptavidin
bridge [11]. We demonstrated that ultrasound molecular imaging using SFRP2-targeted con-
trast increased the average video pixel intensity (VI) of angiosarcoma vessels by 2.2 ± 0.6 VI
compared to the streptavidin control. However, background binding of our control contrast
was higher than expected and we sought to optimize our method to improve specificity. In this
study, we hypothesized that optimizations to our molecular imaging reagents, and protocol
could significantly increase the average video pixel intensity of angiosarcoma vasculature
imaged with SFRP2-targeted contrast agent. We optimized five design parameters: (1) we
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decreased non-specific binding by using NeutrAvidin™-activated microbubbles, and elimi-
nated microbubble aggregation by using a maleimide-thiol linkage rather than using a strepta-
vidin bridge between biotinylated antibodies and microbubbles, (2) we decreased non-specific
binding further by targeting our control contrast with antibodies against chicken IgY, (3) we
used time-intensity curves (TIC) from non-tumor regions of interest (ROI) to generate free-
flowing- corrected TICs for both SFRP2-targeted, and IgY-targeted contrast, which allowed us
to time our molecular imaging acquisition to occur when the ratio between SFRP2-specific
and IgY-specific acoustic signals was at its maximum, (4) we varied the antibody-labeling
index, and (5) we varied the dose of targeted microbubbles. We then applied these optimiza-
tions to determine the performance of our optimized SFRP2-targeted contrast in imaging
angiosarcoma tumors in a murine allograft model.
Material and methods
Cell culture
Murine SVR angiosarcoma cells were acquired from American Type Culture Collection
(ATCC, Manassas, VA). ATCC authenticates cell line identity; furthermore, SVR angiosar-
coma cells tested negative for Ectromelia, EDIM, LCMV, LDEV, MHV, MNV, MPV, MVM,
Mycoplasma, Polyoma, PVM, REO3, Sendai, TME GFVII using PCR analysis performed by
Research Analytic Diagnostic Laboratory (Columbia, MO). Cells were cultured in high-glu-
cose DMEM with 10% fetal bovine serum (Sigma Aldrich, St. Louis, MO) and incubated in a
37˚C humidified room air atmosphere enriched with 5% CO2.
Animal care and husbandry
All animal experiments were performed in accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The
Institutional Animal Care and Use Committee of the University of North Carolina at Chapel
Hill (UNC-CH) approved this study.
The Division of Laboratory Animal Medicine (DLAM) veterinarians, veterinary technicians
and laboratory technicians supervise the health care and humane use of all animals on the
UNC-CH campus, and have been accredited by the Association for the Assessment and
Accreditation of Laboratory Animal Care International (AAALAC) since 1973. As laboratory
animal specialists they provide a comprehensive program of veterinary care, offer technical
advice and assistance, and provide laboratory and pathology services needed for diagnostic
and research purposes.
Veterinary technicians make rounds through all animal facilities on a regular basis to assess
the health status of all animals. Animal husbandry services provided by DLAM include: hous-
ing and husbandry services employing standardized food, bedding, caging, and cage changing
intervals, with daily inspections of all cages; sanitation of cages, equipment and animal rooms;
environmental enrichment; consultation on animal care and use, breeding, species selection,
species specific biology and health care, and testing of sentinel animals for viral and bacterial
pathogens, as well as endo and ectoparasites.
Although not required during this study, if any animal had experienced pain or discomfort
that could not be alleviated with standard analgesics, they would have been humanely eutha-
nized with an overdose of inhaled anesthetic or carbon dioxide, followed by a physical means
of euthanasia. All animals at the end of the study, and any animal with a tumor in excess of 1.5
cm diameter were humanely euthanized as described above.
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Establishment of SVR angiosarcoma allografts in vivo
Injecting 1 x 106 SVR angiosarcoma cells subcutaneously in the right flank of six week-old
nude mice created tumor allografts. Tumor measurements were obtained twice weekly using
B-mode ultrasound on a Vevo2100 (Visual Sonics, Toronto, Ontario, Canada). Ultrasound-
based tumor measurements were performed under isoflurane anesthesia. Molecular imaging
experiments were performed when tumors reached 8 mm in maximal dimension, which typi-
cally occurred after two weeks of growth.
Targeted ultrasound contrast agents were designed with NeutrAvidin™-
activated microbubbles
The amino moiety of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(poly-ethyl-
ene glycol)-2000] (DSPE-PEG2000-Amine) was converted to a sulfhydryl moiety using Traut’s
reagent. The resulting sulfhydryl-activated lipid (DSPE-PEG2000-Thiol) was incorporated at
0.2 mole percent into a lipid solution containing 90 mole percent 1,2-distearoyl-sn-glycero-
3-phosphocholine (DSPC), 9.8 mole percent 1,2-distearoyl-sn-glycero-3-phospho-ethanol-
amine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000), 15% (v/v) propylene glycol,
5% (v/v) glycerol in phosphate buffered saline (PBS). Sulfhydryl-activated ultrasound contrast
(Fig 1A) was prepared by shaking the lipid solution in glass vials containing decafluorobutane
(DFB) gas using a VialMix (Lantheus Medical Imaging, N. Billerica, MA). Given that the head
group of phosphatidylcholine occupied 0.71 square nm, we calculated that a 4 μm diameter
microbubble could accommodate 1 × 108 lipid molecules. The thiol content of our microbub-
ble preparations were calculated based on the mole percentage of the DSPE-PEG2000-thiol,
the average diameter and total number of microbubbles.
NeutrAvidin™ (Pierce Biotechnology, Rockford, IL) is a deglycosylated, neutral form of avi-
din with less nonspecific binding properties than native avidin. 3 or 10-fold molar excess of
maleimide-activated NeutrAvidin™ was reacted with sulfhydryl-activated ultrasound contrast
Fig 1. SFRP2-targeted and control ultrasound contrast agents were designed with NeutrAvidin™. (A) Sulfhydryl-activated
lipid solution was formulated by incorporating a thiol functionalized PEG-lipid (DSPE-PEG2000-thiol) at 0.2 mole percent in our lipid
solution. Thiol-activated contrast agent was prepared by shaking the lipid solution in 3 ml glass vials containing perfluorobutane gas
(see Methods for details). (B) NeutrAvidin™ functionalized contrast agent was prepared by forming a covalent crosslink between
maleimide-activated NeutrAvidin™ and thiol-activated contrast agent. We estimated the thiol content of our sulfhydryl-activated
contrast agent and tested 3 and 10-fold molar excess of maleimide-activated NeutrAvidin™. (C) Anti- SFRP2 targeted or control
anti-chicken IgY targeted microbubbles were prepared by adding a 3-fold molar excess of either biotinylated SFRP2 antibodies or
biotinylated antibody to chicken IgY to NeutrAvidin™ functionalized, ultrasound contrast agents.
https://doi.org/10.1371/journal.pone.0174281.g001
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according to the manufacturer’s protocol to prepare NeutrAvidin™-coated microbubbles (Fig
1B). Unbound NeutrAvidin™ was removed by three sequential washes with PBS. NeutrAvi-
din™-coated microbubbles were stored at a concentration > 1 × 109 microbubbles/ml at 4˚C
until needed for creation of targeted contrast.
Incubating biotinylated SFRP2 antibodies with NeutrAvidin™-coated microbubbles created
SFRP2-targeted ultrasound contrast agent (Fig 1C). Three polyclonal antibodies (two raised in
goat and one in rabbit) against different epitopes of SFRP2 were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA) sc-7426 (goat, C-18), sc-13940 (rabbit, H-140), and sc-31574
(goat, D-20). These antibodies were biotinylated using EZ-Link Sulfo-NHS-LC-Biotinylation
Kit (Pierce Biotechnology) according to the manufacturer’s instructions. Unbound antibodies
were removed by three sequential washes with PBS. SFRP2-targeted microbubbles were stored
at a concentration of> 1 × 109 microbubbles/ml at 4˚C until needed for molecular imaging.
Incubating biotinylated polyclonal control antibodies with NeutrAvidin-coated microbub-
bles created control ultrasound contrast agent. Biotinylated polyclonal control antibodies were
raised in either rabbit or goat against chicken IgY (Bethyl Laboratories, Montgomery, TX),
and were used in the same 2:1 ratio of goat to rabbit as used with the SFRP2-targeted ultra-
sound contrast agent.
A typical size distribution for anti-SFRP2 targeted contrast or the control anti-chicken IgY
targeted contrast was: 2.1±1.3 μm diameter, with a mode of 1.6 μm, and median diameter of
1.7 μm.
Molecular imaging with SFRP2-targeted, and IgY-targeted control
contrast agents
Molecular imaging of SFRP2 expression was performed with the SFRP2-targeted and control
contrast agents as previously described [11], and as illustrated in Fig 2. Briefly, animals were
anesthetized with isoflurane and tail vein catheters were placed. Three dimensional ultrasound
scans were captured using a Lab View (National Instruments, Austin, TX) controlled motion
stage that coordinated transducer motion and image acquisition. Three-dimensional B-mode
ultrasound images were obtained at 15 MHz using a 15L8 linear array transducer with a Sie-
mens imaging system (Acuson Sequoia 512, Mountain View, CA). B-mode images allowed
selecting the region of interest (ROI) in each imaging plane and allowed measuring tumor vol-
ume. Cadence™ pulse sequence (CPS) mode, a nondestructive contrast-specific imaging tech-
nique operating at 7 MHz (mechanical index = 0.18, CPS gain = –7 dB, dynamic range = 80
dB) was used to image targeted and control contrast agents.
Molecular imaging of SFRP2 expression with time-intensity curves. The average video
pixel intensity within our 3D ROIs was used to plot time-intensity curves (TICs) to better
understand the natural decay of contrast within the tumor after bolus injection (Figs 2 and 3).
Cadence™ mode images were captured immediately after bolus injection of contrast agent,
then every 30 seconds for 2 minutes (to establish peak), followed by every 2 minutes for 20
minutes (to establish washout). ROIs were defined using the anatomical features of the B-
mode image with occasional guidance from the contrast-specific, Cadence™ image. The non-
tumor ROI was drawn in a similar fashion, at approximately the same tissue depth as the
tumor, avoiding any signal artifacts present on the baseline CPS image. The ROIs were not
matched in pixel size since the metric for comparison was the average video pixel intensity.
The peri-tumoral region was used to approximate the signal from free-flowing contrast present
in the vasculature with the assumption that no contrast was bound outside of the tumor ROI.
Average video pixel intensities for the tumor, and peri-tumoral regions were calculated for
each contrast at every time point, and the best-fit model for signal decay was determined using
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GraphPad Prism. We also calculated a ‘free-flowing-corrected’ TIC for SFRP2 or IgY-targeted
contrast by subtracting the relevant peri-tumoral average pixel intensity (Fig 3A, 3B and 3E).
To determine the optimal time for image acquisition after contrast bolus, we compared
TICs for SFRP2-targeted contrast to control contrast. Five animals received a control contrast
bolus followed by SFRP2-targeted contrast, under one episode of anesthesia. The greatest dif-
ference between the ‘free-flowing-corrected’ TICs for SFRP2-targeted and IgY-control con-
trast began to plateau at 10 minutes, and this time point was selected as the optimal time to
acquire data for molecular imaging (Fig 3E and 3F).
Molecular imaging of SFRP2 expression using the ‘image—destroy—image’ method to
subtract the contribution of free flowing contrast. Molecular imaging of SFRP2 expression
was performed with the SFRP2-targeted and control contrast agents as previously described
[11], as illustrated in Fig 2B.
Fifty μl of microbubble contrast was injected into the tail vein. At the specified time after
bolus injection (discussed below), Cadence™ mode 3D scans of the tumor and surrounding tis-
sue were performed to determine the average video pixel intensity contributed by microbubble
contrast that remained within the tumor and surrounding tissue, and was referred to as the
‘pre-destruction’ scan. The Acuson Sequoia was preconfigured with a ‘D color’ scan setting
that provided a short burst of high mechanical index ultrasound that destroyed microbubbles
present in the field of view. After using high-energy D color scans to destroy all freely flowing,
Fig 2. 3-dimensional molecular imaging protocols estimated video intensity of free flowing contrast, with and without destruction of
microbubbles. Prior to injection of targeted contrast agent, anatomical features were recorded with a B-mode scan (black arrow). The first
contrast-specific, Cadence™ contrast pulse sequencing scan was performed in the absence of contrast (blue line capped with open circle) to
establish the average video pixel intensity (VI) of ROIs at baseline. (A) Time-intensity curves (TICs). A ‘non-destructive imaging scheme’ captured
multiple Cadence™mode scans during the first 2 minutes post-injection to capture wash-in of the contrast bolus, and then every two minutes
between 2 to 20 minutes post-injection. Average video pixel intensities from a representative study were plotted, showing total signal from tumor
ROIs (black line) and from non-tumor ROIs (dotted blue line). The TIC from non-tumor ROIs was used later to approximate the signal contributed
by freely flowing contrast. (B) An image—destroy—image’ scheme was used to differentiate targeted contrast bound within tumor endothelium
from targeted contrast flowing freely in the vasculature. A Cadence™mode scan was captured at a pre-determined time (10 minutes, pre-
destruction scan, blue arrow) to determine the average video pixel intensity in the tumor ROI. This was followed immediately by a high mechanical
index (D-Color) scan to destroy all bound and freely flowing contrast within the tumor ROI (red arrow, destructive scan). A pause of 60 seconds
allowed freely flowing contrast to re-enter the tumor vasculature, and a final Cadence™mode scan was captured (12 minutes, post-destruction
scan, blue arrow) to estimate the average VI contributed by freely flowing contrast. The average video pixel intensity contributed by contrast bound
to endothelium was calculated by subtracting the average VI of the post-destruction scan from the average VI of the pre-destruction scan. Average
video pixel intensity for all scans was reported after subtracting the average video pixel intensity of the baseline scans.
https://doi.org/10.1371/journal.pone.0174281.g002
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Fig 3. Time-Intensity Curves (TICs) generated from a representative animal that received both SFRP2-targeted, and IgY-targeted control
contrast. (A) SFRP2-targeted contrast: solid blue line represents intensity within the tumor ROI, dotted black line represents intensity within a non-
tumor ROI, red filled circles represent the difference between the tumor and non-tumor ROI intensities, which we term ‘free-flowing-corrected’ TIC (ffc-
TIC). (B) IgY-targeted contrast: solid green line represents intensity within the tumor ROI, dotted black line represents intensity within a non-tumor
ROI, purple open circles represent the difference between the tumor and non- tumor ROI intensities, which we term ‘free-flowing-corrected’ TIC (ffc-
TIC). (C) The wash out of contrast from tumor ROI was modeled by one-phase exponential decay for IgY-targeted contrast (raw data, open green
circles; green line, best-fit model), and by a plateau followed by one-phase exponential decay for SFRP2-targeted contrast (raw data, solid blue
circles; blue line, best-fit model). (D) The difference between the models depicted in panel (C) was plotted with open black triangles. Note the maxima
between 6–10 minutes. (E) The ffc-TICs for SFRP2, and IgY-targeted contrast were fitted to curves. A one-phase association model (grey line) fit the
wash in portion of the ffc-TIC for SFRP2-targeted contrast (red filled circles), and for IgY-targeted contrast (open purple circles). The wash out of
SFRP2-targeted ffc-TIC was best fit with a linear regression model (blue line), while the wash out of IgY-targeted ffc-TIC was best fit with a one-phase
Optimizing ultrasound molecular imaging of SFRP2 expression in angiosarcoma
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and all bound contrast agents within the scan volume, a second 3D Cadence™ mode scan was
acquired, and was referred to as the ‘post-destruction’ scan. This final scan established the
video pixel intensity attributable to free-flowing contrast remaining in the vasculature. The
amount of contrast bound within any ROI was determined by subtracting the average post-
destruction video pixel intensity from the average pre-destruction pixel intensity (Fig 2B).
Average video pixel intensity for all scans was reported after subtracting the average video
pixel intensity of the baseline scans.
Optimizing antibody-loading of targeted contrast agents by increasing
NeutrAvidin™-labeling of microbubbles
We created two formulations of SFRP2-targeted microbubble contrast to improve contrast
binding to tumor. Sulfhydryl-activated microbubbles (0.2 mole percent) were incubated in
either 3- or 10-fold molar excess of maleimide-activated NeutrAvidin™. Biotinylated SFRP2
antibodies were then bound to NeutrAvidin™ microbubbles as described above. If sulfhydryl
moieties were left unmodified after the reaction with 3-fold molar excess of NeutrAvidin™,
higher antibody binding would be expected after using a 10-fold molar excess of NeutrAvi-
din™. Eight animals received 5 x 106 microbubbles of both the 3- and 10-fold molar excess for-
mulations and were imaged 10 minutes after bolus injection. Tumor and adjacent tissue
perfusions using both formulations were compared in each animal.
Optimizing contrast agent dose
To determine the optimal dose of SFRP2-targeted and control microbubble contrast, we cre-
ated four formulations of contrast: 5 × 106 per 50 μl and 5 × 107 per 50 μl for both SFRP2-tar-
geted and control contrast. Ten animals received doses of 5 × 106 followed by 5 × 107 of either
SFRP2-targeted or control contrast. Contrast enhancement in tumor and adjacent tissue was
compared in each animal using all contrast formulations.
Testing optimized molecular imaging reagents, and protocol in vivo
To verify the performance of our optimized contrast agents, we performed molecular imaging
of 10 animals with control contrast, followed by SFRP2-targeted contrast using the ‘image—
destroy—image’ scheme illustrated in Fig 2B. Cadence™ mode images were captured 10 min-
utes after bolus injection to determine the amount of bound contrast. A final Cadence™ mode
scan was captured, after destroying all contrast within the scan region, to detect free-flowing
contrast. Contrast injection and molecular imaging were performed for both contrast agents
under a single episode of anesthesia. The SFRP2-targeted contrast was injected 10 minutes
after the completion of the control contrast scans to ensure adequate washout of control
microbubbles. Retention of contrast agents in tumor and non-tumor tissue was compared in
each animal for both contrast agents.
The relationship between microbubble acoustic signal, and video pixel
intensity
Microbubble signal in arbitrary acoustic units (AU), spanned a dynamic range of 80 dB, and
was log compressed to fit within an 8-bit range so that it could be represented visually. We
exponential decay model (green line). (F) The best-fit model for the IgY-targeted ffc-TIC was subtracted from the best-fit model for SFRP2-targeted ffc-
TIC, and was plotted (red filled circles with red line). This produced a TIC representing the signal intensity within the tumor ROI that could be attributed
to binding of contrast specifically mediated by the SFRP2 antibodies used to formulate the SFRP2-targeted contrast. N = 5 animals.
https://doi.org/10.1371/journal.pone.0174281.g003
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calculated average video pixel intensities (VI) from these images, which served as a logarithm-
based measure of changes in acoustic signal. To estimate linear changes in acoustic signal, it
was necessary to log decompress average VI values using Eq 1 [12]:






Substitution into Eq 1 showed that the ratio of any two acoustic signals estimated from
their average video pixel intensities (VI) was proportional to a power function with an expo-
nent of ΔVI = (VI2 –VI1). From the Law of Exponents, the ratio of any two acoustic signals
was proportional only to ΔVI, and could not be calculated by making a ratio between the two
VI values (Fig 4). Log decompression estimated the original acoustic signal since ultrasound
Fig 4. The relationship between microbubble acoustic signal, and log compressed video pixel intensity. (A) The acoustic signal from
microbubbles in arbitrary acoustic units (AU) was log compressed from a dynamic range of 80 dB to an 8-bit range (0–255) of video pixel intensities
(VI). Given video pixel intensities (VI), log decompression with Eq 1 was used to estimate the original acoustic signal in AU, and was plotted to show
their non-linear relationship over the entire 8-bit range. (B) A linear relationship existed between video pixel intensities (VI), and their corresponding
acoustic signals (AU), when VI was < 20. This linear relationship represented a range of acoustic signals limited to ~ 0.025–0.055 AU. (C) The ratio of
any two video pixel intensities (VI) was not related linearly to the ratio of their estimated acoustic signals. (D) However, the ratio between log-
decompressed acoustic signals (AU2 AU1) was related linearly to Δ VI = (VI2 –VI1). Computing ΔVI resulted in a metric that was proportional to the
ratio of the original acoustic signals: a natural consequence of the Law of Exponents. Linear regression provided the best-fit equation: (AU2 AU1) =
0.0529 × ΔVI + 0.9455, with R2 = 0.992 describing the relationship between ΔVI, and (AU2 AU1) when ΔVI < 20.
https://doi.org/10.1371/journal.pone.0174281.g004
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scanners may perform additional proprietary transforms of acoustic data before displaying the
video data.
Statistics
Custom MATLAB (Mathworks, Natick, MA) scripts were used to determine baseline- sub-
tracted, average video pixel intensity (VI) of tumor and adjacent tissue using video data from
DICOM files. Two-tailed, paired or unpaired t-test, were used to compare groups in the opti-
mization experiments, as appropriate. Curves were fit to data, and plotted with GraphPad
Prism (version 7.0a for Mac OS X, GraphPad Software, La Jolla CA, USA, www.graphpad.
com). A p-value of 0.05 was considered significant. Statistical analyses were performed using
SPSS (version 20, IBM, Armonk, New York) or GraphPad Prism.
Results
Molecular imaging of SFRP2 with time-intensity curves
Fig 3 depicts TICs for a representative animal receiving both SFRP2-targeted and control con-
trasts. We observed similar, rapid wash in peaks for both the SFRP2-targeted and control con-
trast agents, and relatively fast wash out of the contrast agents, which was expected given the
short half-life of microbubble contrast (IgY-targeted T½ = 3.0 minutes, 95% CI = 2.8–3.3 min-
utes). Slower wash out occurred using the SFRP2-targeted contrast, secondary to SFRP2 bind-
ing to tumor vasculature (SFRP2 T½ = 17.3 minutes, 95% CI = 12.1–30.0 minutes). There were
no differences in peak signal intensity between the SFRP2-targeted and control contrast groups.
The wash out of IgY-targeted contrast was best fit with a one-phase decay model where:
Y = signal intensity, Y0 = signal intensity at time zero, x = time, k = rate constant, and
Plateau = signal intensity at infinite time (Fig 3C).
Y ¼ Plateau þ ðY0   PlateauÞ  e
ð  kxÞ ð2Þ
However, the washout of SFRP2-targeted contrast (Fig 3C) was best fit with a model using a
plateau followed by one-phase decay where: x = time, x0 = time when decay begins, and
remaining variables were as defined for Eq 2.
Y ¼ Plateau þ ðY0   PlateauÞ  e
ð  k½x  x0 Þ ð3Þ
Constants for the best-fit curves representing wash out of contrast from the tumor ROI
(Eqs 2 and 3) are presented in Table 1.
The wash out of contrast from non-tumor ROIs was modeled using a one-phase decay.
Coefficients for the best-fit models describing wash out of contrast from non-tumor ROIs are
presented in Table 2.
Table 1. Best-fit values described nonlinear curves for wash out of contrast.
Contrast SFRP2 targeted IgY targeted
ROI Tumor Tumor
Curve Plateau followed by one phase decay One phase decay
Constant Value ± SE 95% CI Value ± SE 95% CI
x0 3.28 ± 0.223 2.72 to 3.75 n/a n/a
Y0 31.9 ± 0.205 31.4 to 32.3 39.5 ± 0.524 38.3 to 40.7
Plateau -15.1 ± 6.37 -39.7 to -4.97 3.61 ± 0.232 3.07 to 4.12
x 0.0401 ± 0.00768 0.0231 to 0.0573 0.23 ± 0.0076 0.213 to 0.248
Half-life 17.3 12.1 to 30.0 3.01 2.80 to 3.25
https://doi.org/10.1371/journal.pone.0174281.t001
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The maximum difference between SFRP2-targeted, and IgY-control TICs occurred
before the IgY-control TIC reached minimal levels. Among the 5 animals that received
both contrasts, the maximal difference between SFRP2-targeted and control contrast agents
occurred between 4 and 12 minutes after injection. For the animal depicted, the maximal dif-
ference between the best-fit models for the SFRP2, and IgY control contrasts occurred between
6–8 minutes post-injection (Fig 3D). However, it required 10 minutes for the IgY-control
TIC’s signal-to-noise ratio to fall to minimal levels (Fig 3C). We let the average video pixel
intensity of the IgY-control TIC at infinite time (plateau) to represent the ‘noise’ level (Table 1,
3.6 ± 0.2 VI); ‘minimal’ was defined as a signal-to-noise ratio < 2.
Non-tumor ROIs were used to define ‘Free-Flowing-Corrected’ TICs (ffc-TICs). We
estimated the amount of signal contributed by ‘free-flowing’ contrast by assuming that no con-
trast was bound by non-tumor tissue, and plotting the TIC of non-tumor ROIs (dotted lines in
Fig 3A and 3B). By subtracting the ‘free-flowing’ TIC from the tumor TIC, we established
‘free-flowing-corrected’ TICs (ffc-TICs) for SFRP2 and ffc-TICs for IgY-targeted contrast (Fig
3A, 3B and 3E). As expected, the wash in of the ffc-TICs fit a model of pseudo-first order kinet-
ics for one-phase association (Fig 3E). The wash out of the SFRP2-targeted ffc-TIC was best fit
with a straight line. However, the wash out of the IgY-targeted ffc-TIC was best fit with a one-
phase exponential decay (Table 3). Peak intensity of the IgY-targeted ffc-TIC occurred 4 min-
utes after injection (11.5 VI) compared to the 10 minutes required for the SFRP2-targeted ffc-
TIC to come to a slightly higher maximum (15.4 VI).
The plateau in the control-subtracted, SFRP2-specific, ffc-TIC coincided with the opti-
mal time to deploy the ‘image—destroy—image’ sequence for molecular imaging of
SFRP2. The IgY-targeted ffc-TIC represented binding of contrast within the tumors that was
not mediated by our mixture of SFRP2 polyclonal antibodies. By subtracting the IgY-targeted
ffc-TIC from the SFRP2-targeted ffc-TIC, we were left with the contrast signal that could be
directly attributed to contrast retained in the tumor specifically by the SFRP2 antibodies. 10
minutes after injection, the IgY-control-subtracted, SFRP2-targeted ffc-TIC reached a plateau
Table 2. Best-fit values described models for wash out of contrast from non-tumor ROI.
Contrast SFRP2 targeted IgY targeted
ROI Non-tumor Non-tumor
Curve One phase decay One phase decay
Constant Value ± SE 95% CI Value ± SE 95% CI
Y0 33.8 ± 0.539 32.7 to 35.1 35.1 ± 1.24 35.5 to 37.9
Plateau -7.40 ± 2.14 -13.3 to -3.47 -0.0792 ± 0.406 -0.994 to 0.781
k 0.0746 ± 0.00768 0.0580 to 0.0918 0.322 ± 0.0240 0.275 to 0.376
Half-life 9.29 7.55 to 11.9 2.15 1.84 to 2.52
https://doi.org/10.1371/journal.pone.0174281.t002
Table 3. Best-fit values described models for ffc-TICs.
Contrast SFRP2 targeted IgY targeted
ROI Tumor Tumor
Curve Linear One phase decay
Constant Value ± SE 95% CI Constant Value ± SE 95% CI
Slope -0.337 ± 0.029 -0.417 to -0.257 Y0 16.5 ± 0.782 14.8 to 18.63
Y-intercept 18.8 ± 0.443 17.5 to 20.0 Plateau 1.68 ± 0.676 -0.706 to 2.946
X-intercept 55.6 47.8 to 68.2 k 0.104 ± 0.0146 0.0690 to 0.140
r2 0.9717 Half-life 6.685 4.94 to 10.0
https://doi.org/10.1371/journal.pone.0174281.t003
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of ~ 8.8 VI (Fig 3F). 10 minutes post-injection also corresponded to the point when the ffc-TIC
for SFRP2-targeted contrast reached its maximum (Fig 3E), and also when the IgY-targeted
TIC (Fig 3C) fell below twice the ‘noise’ level (Table 1, ‘plateau’ represents VI at infinite time).
Accordingly, we chose 10 minutes as the optimal time point to obtain targeted molecular
images for the remaining experiments.
Increased NeutrAvidin™-labeling of microbubbles increased contrast
enhancement
SFRP2-targeted contrast created using 10-fold molar excess of maleimide-activated NeutrAvi-
din™ detected tumor vasculature with greater average video pixel intensity (4.53 ± 0.185 vs.
0.316 ± 0.150 VI, P<0.001) compared to control contrast formulated with 3-fold molar excess
(Fig 5). Greater video intensity likely occurred secondary to higher antibody conjugation to
the microbubbles, which therefore facilitated more frequent antibody-SFRP2 interactions
within the tumor vasculature. There were no significant differences in signal intensity within
the peri-tumoral tissue (not shown).
Labeling with maleimide-activated NeutrAvidin™ was nearly saturated. The change in
VI from 0.32 to 4.53 VI represented a Δ VI of 4.2 for a dose of 5 × 106 microbubbles. Since
video pixel intensity (VI) represented microbubble acoustic signal in arbitrary acoustic units
Fig 5. Average video pixel intensity increased with higher levels of NeutrAvidin™ labeling.
Significantly higher tumor video pixel intensity was observed when SFRP2-targeted contrast was created
using 10-fold molar excess of maleimide-activated NeutrAvidin™ compared to 3-fold molar excess. N = 8
animals.
https://doi.org/10.1371/journal.pone.0174281.g005
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(AU) after log compression, Δ VI of 4.2 represented a 1.15 fold increase in the original micro-
bubble acoustic signal (AU) after log decompression.
Thus, a 333% change in maleimide-activated NeutrAvidin™ (from 3 to 10-fold molar excess)
only resulted in a 15% change in microbubble acoustic signal. This small increase in microbub-
ble acoustic signal (AU) indicated that the maleimide moiety was near saturation for micro-
bubbles formulated with a sulfhydryl content of 0.2 mole percent.
We considered testing a 100-fold molar excess of maleimide-activated NeutrAvidin™ but rea-
soned that the increase in linearized video signal might not match the previous 15% change.
Increasing the molar excess of the maleimide moiety from 10 to 100-fold would have required
increasing maleimide-activated NeutrAvidin™ from 500 mg per 1 × 1010 microbubbles to 5 mg
per 1 × 1010 microbubbles; the cost to benefit ratio seemed high. In addition, since maleimide-
activated NeutrAvidin™ was activated with an average of 4 moles of maleimide per mole of Neu-
trAvidin™, it was multivalent for sulfhydryl moieties making microbubble aggregation a real
possibility at higher concentrations. Assuming the increase from 10 to 100-fold molar excess
resulted in an additional 10% increase in microbubble acoustic signal, the total increase from
3-fold molar excess would have been 1.26 fold. This would have represented an increase in VI
from 0.32 to 6.32, equivalent to a 26% increase in microbubble signal for a 33,000% increase in
maleimide-activated NeutrAvidin™, which was an extremely high cost to benefit ratio.
Thus, we reasoned that 3 and 10-fold molar excess of maleimide-activated NeutrAvidin™
represented reasonable minimum, and maximum values respectively for the covalent attach-
ment of maleimide-activated NeutrAvidin™ to 0.2 mole percent sulfhydryl-activated micro-
bubble contrast.
Optimizing contrast agent dose
Dose optimization was performed with SFRP2-targeted contrast formulated using 10-fold
molar excess of maleimide-activated NeutrAvidin. SFRP2-targeted contrast injected as a bolus
of 5 × 107 microbubbles detected tumor vasculature with greater signal intensity compared to
a bolus of 5 × 106 microbubbles (Fig 6, 21.2 ± 2.53 vs. 4.53 ± 0.185 VI, p<0.001). There were
no significant differences in signal intensity of peri-tumoral tissue, and peri-tumoral tissue
retained significantly less contrast than tumor tissue (not shown).
Contrast agent dose was approaching saturation. Increasing the dose of targeted micro-
bubbles from 5 × 106 to 5 × 107 resulted in a change in VI from 4.5 to 21.2 VI, a Δ VI of 16.7.
This ΔVI corresponded to ~ 83% increase in acoustic signal for a 1,000% increase in microbub-
ble dose. Although the percentage increase observed after changing microbubble dose was more
robust than what was seen for changing antibody labeling index, we expected approximately
10-fold higher change if the microbubble dose was not near saturation. We concluded that fur-
ther increases in microbubble dose might have provided a limited increase in acoustic signal.
However, the recommended dosing of Definity1 Perflutren Lipid Microspheres for human
echocardiograms was 10 μL per kg of body weight. Assuming a patient mass of 154 lb. = 70 kg,
a typical blood volume of 4.7 liters, and a maximum microbubble concentration of 1.2 × 1010
per ml, the recommended bolus dose of 0.7 ml provided 8.4 × 109 microbubbles or 1.8 × 106
microbubbles per ml of blood. Our nude mice weighed approximately 25 g, and were expected
to have a total blood volume of 2.3 ml [13]. Bolus doses of 5 × 106, and 5 × 107 microbubbles
resulted in 2.2 × 106, and 22 × 106 microbubbles per ml of blood, approximately 1.2 × and
12 × the recommended human bolus dose.
A higher contrast agent dose of 5 × 108 was considered but was expected to have several
drawbacks. First, the time required for the majority of freely flowing contrast to clear from cir-
culation was expected to increase dramatically, compared to a dose of 5 × 107 microbubbles.
Optimizing ultrasound molecular imaging of SFRP2 expression in angiosarcoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0174281 March 23, 2017 13 / 21
The more important consideration was that 5 × 108 microbubbles represented ~220 × 106
microbubbles per ml of blood, equivalent to ~120 × the recommended human bolus dose. A
lower dose of 5 × 105 microbubbles was also considered but was rejected since lower signal
intensity was not our goal. Accordingly, we decided that 5 × 106, and 5 × 107 represented the
minimum, and maximum doses respectively of targeted microbubbles for molecular imaging
of SFRP2 expression in angiosarcoma.
Significantly improved performance of optimized molecular imaging
reagents, and protocol verified in vivo
SFRP2-targeted and IgY-targeted control contrast agents were created using 10-fold molar
excess of maleimide-activated NeutrAvidin, and delivered in bolus doses of 5 × 107 microbub-
bles per 50 μl. Molecular imaging data was captured 10 minutes after bolus injection using the
‘image—destroy—image’ scheme (Fig 2B). Cadence mode images from a representative ani-
mal illustrated the wash in and preferential retention of SFRP2-targeted contrast in tumor
compared to the control IgY-targeted contrast (Fig 7). Using these optimizations, SFRP2-tar-
geted contrast detected 14.2 ± 3.0 VI greater average video pixel intensity compared to the
IgY-control in tumor vasculature (Fig 8: 22.1 ± 2.5 vs. 7.9 ± 1.6 VI, p<0.001). The specificity
of our SFRP2-targeted contrast for tumor vasculature was confirmed by the minimal signal
Fig 6. Average video pixel intensity increased with increased microbubble dose. Significantly higher
video pixel intensity was observed in tumors when animals received 5 × 107 SFRP2-targeted microbubbles
compared to 5 × 106 SFRFP2-targeted microbubbles. N = 10 animals.
https://doi.org/10.1371/journal.pone.0174281.g006
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Fig 7. Ultrasound molecular imaging of animal receiving SFRP2-targeted and control IgY-targeted
contrast. A white dashed line outlines tumors. The contrast-specific signal (green) was superimposed over
the b-mode image (grey). At 30 seconds, average video pixel intensity was similar between control and
SFRP2-targeted contrast. The contrast-specific video intensity was retained in tumors at much higher levels
when using the SFRP2-targeted contrast compared to the IgY-targeted contrast.
https://doi.org/10.1371/journal.pone.0174281.g007
Fig 8. Verifying performance of optimized molecular imaging reagents, and protocol in vivo. Non-
identical superscripts indicate a statistically significant difference in means. Both IgY-targeted (a, p = 0.03),
and SFRP2-targeted (c, p < 0.001) contrast produced significantly higher video pixel intensities in tumor ROI
compared to peri-tumoral regions (b). SFRP-2 targeted contrast (c, p < 0.001) produced significantly higher
signal intensity in tumor ROI than the control IgY-targeted contrast (a). Average video pixel intensities were
corrected for free flowing contrast by subtracting the post-destruction VI from the pre-destruction VI as shown
in Fig 2B for the ‘image—destroy—image’ method. N = 10 animals.
https://doi.org/10.1371/journal.pone.0174281.g008
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intensity for both the SFRP2 and control contrast agents in peri-tumoral vasculature
(3.2 ± 0.52 vs. 1.6 ± 0.71 VI, p = 0.16).
When the IgY-targeted average video pixel intensity was subtracted from the SFRP2-tar-
geted average video pixel intensity, we were left with a value of 14.2 ± 3.0 VI for the tumor.
This value for control-subtracted, SFRP2-targeted video intensity can be attributed solely to
the SFRP2 antibodies that mediated binding of contrast agent to tumor vasculature. These
video intensities were corrected for the contribution of free-flowing contrast by destroying all
bound contrast within the tumor volume, and then measuring the increase in video intensity
caused by contrast agents carried back into the tumor by blood flow.
Half-lives for wash out of contrast from tumor ROIs and from non-tumor ROIs were calcu-
lated from the TICs (Tables 1 and 2). As expected, it took longer for SFRP2-targeted contrast
to wash out from tumor vasculature than the IgY-targeted contrast (5.75 times longer; T½:
17.3 vs. 3.01 minutes; k: 0.0401 ± 0.00768 vs. 0.23 ± 0.0076). The wash out of SFRP2-targeted
contrast from the tumor ROI was also 1.9 times slower than the wash out of SFRP2-targeted
contrast from the non-tumor ROI (T½: 17.3 vs. 9.29 minutes; k: 0.0401 ± 0.00768 vs.
0.0746 ± 0.00768) indicating specificity for tumor vasculature. The wash out of IgY-targeted
contrast from the tumor ROI was 1.4 times slower than its wash out from the non-tumor ROI
(T½: 3.01 vs. 2.15 minutes; k: 0.23 ± 0.0076 vs. 0.322 ± 0.0240). As this ratio was > 1, we con-
cluded that our IgY-targeted contrast was retained at a low level within tumor vasculature; this
presumably represented nonspecific binding attributable to our microbubble phospholipid,
NeutrAvidin™, and/or antibody composition.
Our previous publication compared biotinylated versions of the same polyclonal
SFRP2 antibodies used in the current study, linked to biotinylated microbubbles by a
streptavidin bridge versus control biotinylated microbubbles that were bound to streptavi-
din. The average video pixel intensity for SFRP2-targeted contrast reported in that publica-
tion was 2.17 ± 0.592 VI units higher (n = 13, p = 0.0032) than the streptavidin control
[11]. Our improved ‘image—destroy—image’ scheme in conjunction with our improved
SFRP2-targeted and the IgY-control contrast agents resulted in a significantly higher
enhancement of average video pixel intensity (14.2 ± 3.0 VI, p = 0.0001). Log decompression
of 2.17 Δ VI showed that streptavidin-linked SFRP2-targeted contrast produced ~ 4%
higher acoustic signal (AU) than the streptavidin control. Log decompression of 14.2 Δ VI
showed that NeutrAvidin™-linked SFRP2-targeted contrast produced ~ 70% higher acoustic
signal (AU) than the NeutrAvidin™-linked IgY-targeted control. Our optimized contrast
agents plus optimized molecular imaging protocol produced ~ 18-fold higher control-sub-
tracted acoustic signal for SFRP2-targeted contrast compared to our previously published
result.
Discussion
Angiosarcoma is a highly lethal malignancy of vascular endothelial cells, and new strategies
for molecular-based imaging are needed. We sought to improve ultrasound molecular imag-
ing of secreted frizzled related protein 2, a secreted multi-function protein overexpressed in
angiosarcoma endothelium [9]. We demonstrated improved performance of molecular
imaging using simple optimizations including better timing of image acquisition and higher
doses of contrast created using higher antibody labeling. Microbubble contrast is considered
safe, and we observed no toxicity in animals receiving SFRP2-targeted or control contrast.
SFRP2-targeted imaging provides potential advantages over traditional imaging such as
enhanced tumor specificity and may yield information regarding tumor biology or response
to therapy.
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Improved molecular imaging reagents, and protocols
Methodologically, multiple changes were made in our ultrasound molecular imaging tech-
nique, compared to previous studies. In this study, we omitted a microbubble size-sorting
step, which reduced the time required to prepare different formulations of targeted and con-
trol contrast agents. Secondly, we changed the microbubble-antibody linking molecule from
streptavidin to maleimide-activated NeutrAvidin™. Combining sulfhydryl-activated microbub-
bles with maleimide-activated NeutrAvidin™ reduced the formation of microbubble clusters,
which occurred sporadically when bridging biotin-labeled microbubbles, and biotin-labeled
antibodies with multivalent streptavidin. In addition, we expected the NeutrAvidin™ linking
molecule to have less background binding in tissue, and cause fewer adverse reactions when
used in humans. Although no toxicity studies or histopathology were performed, animals
recovered fully from molecular imaging sessions with our NeutrAvidin™ based, antibody-tar-
geted contrast, and experienced no more discomfort or distress than expected for receiving
isoflurane anesthesia. Third, we directed the targeting of the control contrast with antibodies
to chicken IgY to further reduce the non-specific binding seen when using streptavidin con-
trast as a control. Fourth, compared to previous studies, we sought to systematically identify
the best timing for image acquisition after bolus injection of contrast agent.
Prior to this study, we chose to perform imaging at 18 minutes, as this appeared to be the
time required for all free-flowing microbubbles to clear from the vasculature. Ideally, we
wanted to know when the ratio of SFRP2-targeted contrast to IgY-targeted contrast had
reached a maximum, after subtracting the contribution from freely flowing, unbound contrast.
We used the average VI of a non-tumor ROI to approximate the signal returned by freely flow-
ing contrast (ffc) for both anti-SFRP2 and IgY targeted contrast, and plotted the ffc-corrected
TICs in Fig 3E. By subtracting the ffc-TIC for IgY-targeted contrast from the ffc-TIC for anti-
SFRP2, we showed that the ratio between the ‘bound’ components of SFRP2-targeted and IgY-
targeted contrast plateaued approximately 10 minutes post-injection (Fig 3F). We concluded
that the optimal time to acquire molecular imaging data using the ‘image—destroy—image’
scheme was 10 minutes post-injection because this was when the IgY control-subtracted, ffc-
TIC for SFRP2 reached its maximum (Fig 3F).
Taken altogether, these changes in methodology significantly improved the video pixel
intensity of SFRP2-specific imaging of angiosarcoma tumors compared to the IgY-targeted
control, and provided 18-fold higher acoustic signal from tumor-bound SFRP2-targeted con-
trast than our previous reagents, and protocol [11].
Linearizing Δ video pixel intensity simplified optimization. The optimization of cross-
linking reactions or binding processes generally uses titration to determine when the reaction
or binding is complete. Le Chatelier’s principle allows these reactions to be driven by shifting
the chemical equilibrium to counteract the effect of the excess reagent or increased concentra-
tion of a binding molecule such as an antibody. Empirically, the reaction is complete when it
can no longer shift its equilibrium: eg. the inability to create more NeutrAvidin™-labeled
microbubbles in response to increased concentration of maleimide-activated NeutrAvidin™ or
no further binding of antibody-labeled microbubbles to tumor endothelium in response to
increased input of the antibody-labeled microbubbles.
It is straightforward to assess how close a system is to saturation when inputs and outputs
are measured on a linear scale. It is more problematic when inputs are varied on a linear scale,
and outputs are measured on a log-compressed scale. Since microbubble acoustic signals from
molecular imaging are generally on the very low end of our 80dB dynamic range, the log-com-
pressed video pixel intensity scale has the effect of expanding small changes in the linear acous-
tic scale. In addition, since Δ VI is the unit that is proportional to the ratio of the acoustic
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signals, the relationship between video intensity and microbubble signal becomes even less
intuitive.
When we expressed the changes (Δ VI) observed in our optimization experiments for Neu-
trAvidin™ labeling and for microbubble dose as linearized acoustic signals on an arbitrary
log-decompressed scale, it was clear that our ‘high’ doses produced a very small percentage
increase in the acoustic signal from microbubbles. It would have been possible to ‘optimize’
our conditions using only the log-compressed video intensity scale but it would have required
many more doses to observe saturation, and it was likely that we would have chased diminish-
ing returns by testing higher and higher doses. Log-decompression did not return the actual
acoustic signal of microbubbles since the result was in arbitrary units, and because a variety of
transforms can be applied to acoustic data before it is displayed on an 8-bit video scale but it
was a useful tool to compare the effect of different treatments on a linearized scale.
Molecular imaging of SFRP2 using time-intensity curves. By examining the TICs
obtained from a single animal (Fig 1E), we were able to estimate the video pixel intensity of
freely flowing contrast within the tumor vasculature. Other groups have proposed methods to
measure the amount of free-flowing contrast within vasculature directly [14,15]. We opted to
use the average video pixel intensity in non-tumor ROIs to approximate the amount of free
flowing contrast in the tumor, and corrected the average video pixel intensity of the tumor
ROI accordingly. Using this method the amount of free-flowing-corrected (ffc) SFRP2-tar-
geted contrast bound within the tumor was 15.4 VI for this animal. This value compared quite
favorably to the difference between SFRP2-targeted video intensity, and IgY-control video
intensities corrected for free flowing contrast by the traditional ‘image—destroy—image’
scheme illustrated in Fig 2B (Δ VI = 14.2 ± 3.0 VI, Fig 8).
Our TIC analysis also allowed us to examine the relationship between time, and the amount
of tumor-bound signal directly attributable to the SFRP2 antibodies. Subtracting the IgY- tar-
geted ffc-TIC from the SFRP2-targeted ffc-TIC removed any component of VI that could be
attributed to non-specific binding: by the non-target antibody, the microbubble shell or the
NeutrAvidin used to form the bridge between the two moieties. The calculated value for
SFPR2 antibody-specific video intensity was 8.8 VI for this animal, which was slightly lower
than the average control-subtracted value determined by the ‘image—destroy—image’ method
(Fig 8).
The analyses of our TICs also systematically determined the optimal time for acquiring
molecular imaging data when using the traditional ‘image—destroy—image’ sequence to sub-
tract the contribution of free flowing contrast. In this study, the TICs determined that micro-
bubbles washed out of the system much more quickly than our previous estimate, which was
established by visually assessing free flowing contrast content in real-time, Cadence™ mode
images (10 minutes versus 18 minutes). Other, more rigorous methods [12,16] have been pro-
posed to differentiate between free flowing and bound contrast, however we feel that the analy-
sis of tumor and non-tumor ROIs is straightforward, and simpler. Our method is valid as long
as the assumption holds true that contrast does not bind in non-tumor tissue. As antibody-
antigen binding kinetics might vary in other systems, we recommend performing TICs prior
to validating untested tumors or targeted contrast formulations.
Clinical applications. In a clinical setting, it is not likely that a control targeted-micro-
bubble would be deployed, and the clinician would not have the luxury of determining the
optimal time to employ the traditional ‘image—destroy—image’ scheme (Fig 2B). However, if
TIC data were collected in the same molecular imaging session that terminated with the tradi-
tional ‘image—destroy—image’ sequence, clinicians would be able to establish whether the
amount of targeted-microbubble retained within the tumor had reached a stable level by the
time of the final image acquisition by simply plotting the free-flowing-corrected time-intensity
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curves. This hybrid approach to molecular imaging would provide a metric establishing the
amount of video contrast enhancement in tumor vasculature versus non-tumor tissue; it
would be especially useful if the half-life of targeted contrast agents changed as a consequence
of patient immune response [17,18].
Our study represents one of many possible applications of ultrasound molecular imaging.
Celebi et al recently described the assessment of ischemia reperfusion injury using selectin-tar-
geted microbubbles in a mouse model of testicular torsion [19]. They showed increased micro-
bubble signal in animals receiving torsion, which was even higher in animals receiving torsion
and TNF-α, compared to control. There were no perfusion differences in animals receiving
control contrast. In our laboratory, Shelton et al demonstrated high-resolution super- har-
monic ultrasound molecular imaging using avβ3 integrin in a rat fibrosarcoma model [20].
They demonstrated high-resolution 3D volumes of micro vascular anatomy, and when com-
bined with ultrasound-based acoustic angiography, new opportunities for analyzing relation-
ships between micro vascular anatomy and endothelial targets. Zhang et al used microbubbles
conjugated to two neuropilin-1 targeted antibodies to image tumor angiogenesis in a murine
model of breast cancer [21]. Further possibilities include molecularly targeted drug or gene
delivery, or high-energy ultrasound tumor ablation using microbubbles that target endothelial
biomarkers.
Any immune response generated to targeted microbubble contrast would be undesired:
this would reduce the amount of circulating contrast agent, and could induce adverse reactions
such as anaphylaxis. Thus, translation of SFRP2 targeted contrast to human applications will
require using a humanized antibody, preferably a Fab-fragment that lacks the Fc region, to
minimize immunogenicity, as well as the use of a direct, covalent linkage to the microbubble
shell to eliminate the use of NeutAvidin™, another possible trigger for an immune response.
Ultrasound molecular imaging of SFRP2 represents a novel approach to visualize angiosar-
coma vessels non-invasively. Optimizations to SFRP2 molecular imaging appear to increase
the specificity for tumor vasculature, and may provide new opportunities for targeted molecu-
lar imaging. We expect that our simple optimizations could be applied to most antibody-
linked microbubble ultrasound imaging systems to improve specificity and performance.
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